CLINICAL TRIALS PROFILE FOR VEDOLIZUMAB
✉ Email this page to a colleague
All Clinical Trials for vedolizumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00619489 ↗ | Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | 2007-12-01 | This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases. |
| NCT00783692 ↗ | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease | Completed | Millennium Pharmaceuticals, Inc. | Phase 3 | 2008-12-01 | The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks. |
| NCT00783718 ↗ | Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis | Completed | Millennium Pharmaceuticals, Inc. | Phase 3 | 2009-01-01 | The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks. |
| NCT00790933 ↗ | An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease | Completed | Millennium Pharmaceuticals, Inc. | Phase 3 | 2009-05-22 | The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration. |
| NCT00790933 ↗ | An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease | Completed | Takeda | Phase 3 | 2009-05-22 | The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration. |
| NCT01177228 ↗ | Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | 2007-05-01 | The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative colitis (UC). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for vedolizumab
Condition Name
Clinical Trial Locations for vedolizumab
Trials by Country
Clinical Trial Progress for vedolizumab
Clinical Trial Phase
Clinical Trial Sponsors for vedolizumab
Sponsor Name
